Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

In a combined effort to help COVID-19 researchers the University of Oxford and Cardiff University have launched a series of “living reviews” in Oxford University Press’s new open access journal “Oxford Open Immunology”.

A pile of papers with multicoloured paper clips

The living reviews will summarise literature around one topic and are a response to the speed and volume of COVID-19 immunology research published during the pandemic.

On behalf of the Oxford-Cardiff COVID-19 Literature Consortium, Dr Ewoud Compeer, University of Oxford points out the idea behind this new publishing format: "The field of COVID-19 immunology was seeing new developments and new hypotheses appearing at an extreme pace online in the form of pre-prints. This speed of publishing made literature reviews outdated even before a journal published them. Our 'living reviews' will stay "live" for a designated period, being updated as change happens."

The journal publishes peer reviewed scientific articles, and the annotation enables rapid communication of updated information, but the version of record does not change so provides a history of the scientific developments.

Professor Awen Gallimore, Cardiff University finds similar advantages to the 'live' format of reviews: "Because new information emerges day by day, when you publish something on Monday by the following Friday it may already be out of date. Our living reviews enable as-you-go updates and should represent a useful step towards supporting scientists address the big and trending research questions."

The COVID-19 Literature initiative began with a team of around 100 post-doctoral researchers, DPhil students, and faculty members from the Medical Sciences Division at the University of Oxford reading, reviewing and summarising the latest COVID-19 research from all round the world in order to support frontline researchers.

At Cardiff, the School of Medicine-wide Journal Club, also comprising PhD students, post-docs and ECRs had started a similar initiative. Oxford and Cardiff joined forces to pool expertise around a wider range of disciplines and ensure those on the frontline were up to date with the latest developments in the field.

The living reviews add to a growing body of material from the Oxford-Cardiff COVID-19 Literature Consortium that is available through their website, and popular science blog, and could become a new benchmark for reviewing research in the future.

"We are pleased to be able to support the research community with this new series of Living Reviews from the Oxford-Cardiff COVID-19 Literature Consortium. We're excited to be able to offer this new open annotation functionality to our authors in Oxford Open Immunology and hope that this innovative new format will generate a useful and up to date resource for readers," said Rhiannon Meaden, Senior Publisher at OUP.

"The reviews were like a paint-by-numbers, we knew there were bits missing and new colours were coming in week by week, but it would be years before we got the whole picture," said Luke Davies from Cardiff University, one of the authors of the first published review. "A living review allows us to carefully add to the picture over time, while still delivering an up-to-date snapshot of the field that can aid ongoing research."

The first living reviews to be published are: Viral entry, sensing and evasion, and Dysregulated inflammation drives immunopathology.

 

 

Similar stories

Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease

Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.

MRC funding awarded to Kennedy researchers

Two new projects led by Tal Arnon and Irina Udalova have been awarded Medical Research Council (MRC) funding.

Breakthrough in treatment for Dupuytren’s disease

Injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules is effective in reducing nodule hardness and nodule size.

New research suggests targeting blood vessels could be key to controlling fibrotic disease

By studying blood vessels at single cell resolution, Professor Jagdeep Nanchahal and colleagues found that in Dupuytren’s disease, a fibrotic disorder of the hand, the vasculature is key to orchestrating the development of human fibrosis.

Defining the role of resident memory B cells in the fight against influenza

Researchers at the Kennedy Institute of Rheumatology have used 3D and live-imaging to show how resident memory B cells boost antibodies to fight influenza.

A blood atlas of COVID-19 defines hallmarks of disease severity and specificity

The COVID-19 Multi-omic Blood Atlas (COMBAT) has identified blood hallmarks of COVID-19 involving particular immune cell populations and their development, components of innate and adaptive immunity, and connectivity with the inflammatory response.